[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":112},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,66,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100641458","dacc-targeted-temporal-interference-for-negative-and-cognitive-symptoms-in-schizophrenia-100641458",false,"NCT07658898","dACC-Targeted Temporal Interference for Negative and Cognitive Symptoms in Schizophrenia","A Randomized Controlled Trial Exploring the Efficacy of Temporal Interference Stimulation for Negative Symptoms and Cognitive Impairment in Schizophrenia","Inclusion Criteria:\n\n* All of the following criteria must be satisfied for enrolment:\n\n  1. A confirmed diagnosis of schizophrenia established according to the criteria set forth in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5);\n  2. Age between 18 and 65 years, regardless of sex, with completion of at least junior secondary education and the capacity to undergo neurocognitive testing;\n  3. Clinically meaningful negative symptoms, operationalized as a PANSS negative symptom subscale (PANSS-NS) total score ≥ 20 with a rating of ≥ 3 on a minimum of one individual PANSS-NS item ; the PANSS positive symptom subscale score must additionally not exceed 19;\n  4. Objective cognitive impairment evidenced by an age- and sex-adjusted composite z-score of ≤ -1.0 on the Chinese version of the Brief Assessment of Cognition in Schizophrenia (BACS), reflecting performance at least one standard deviation below normative values derived from Mandarin-speaking populations;\n  5. Maintenance on an unchanged antipsychotic regimen - with no modification to medication type or dose - for at least 30 days prior to informed consent and continuing throughout the trial;\n  6. Voluntary agreement to participate, documented by written informed consent following thorough explanation of study objectives and procedures; where applicable, a legally authorized representative may provide or co-sign consent.\n\nExclusion Criteria:\n\n* Individuals will be ineligible if any of the following conditions apply:\n\n  1. A concurrent psychiatric diagnosis requiring active clinical management, including but not limited to major depressive episode or bipolar disorder, or the presence of a comorbid neurological disorder or serious physical illness;\n  2. Current or past substance use disorder, encompassing problematic consumption of alcohol or illicit substances;\n  3. A documented seizure disorder or marked electroencephalographic abnormalities, particularly epileptiform activity;\n  4. Evidence of structural brain pathology, including organic lesions, prior traumatic brain injury, or previous neurosurgical intervention;\n  5. Presence of ferromagnetic implants or any other contraindication to MRI or tTIS exposure, including intracranial metallic clips, implanted cardiac devices, or cochlear implants;\n  6. Current use of glucocorticoids or other pharmacological agents known to meaningfully alter cortical excitability;\n  7. Prior exposure to any neuromodulatory intervention - including modified electroconvulsive therapy (MECT), repetitive transcranial magnetic stimulation (TMS), or transcranial direct current stimulation (tDCS) - within the 30 days preceding enrolment.","ALL","18 Years","65 Years",{"count":20,"type":21},62,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized, double-blind, sham-controlled trial aims to evaluate the efficacy and safety of dorsal anterior cingulate cortex-targeted temporal interference stimulation in individuals with schizophrenia. Participants will be randomly assigned to receive either active or sham stimulation for 10 sessions over two consecutive weeks. The primary outcome is the change in negative symptoms, assessed using the Negative Symptom Subscale of the Positive and Negative Syndrome Scale. Cognitive performance, detailed dimensions of negative symptoms, psychosocial functioning, quality of life, and treatment-related adverse events will also be evaluated. Neuroimaging assessments will be conducted before and after the intervention to explore potential neural mechanisms underlying the clinical effects of temporal interference stimulation.",[27],"Schizophrenia Disorder","NOT_YET_RECRUITING","2026-06-23",{"date":31,"type":32},"2026-06-26","ACTUAL",{"date":34,"type":21},"2026-06-30",{"date":36,"type":21},"2027-12-30",{"name":38,"class":39},"Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":40},"100608210","accelerated-rtms-therapeutic-approach-for-refractory-obsessive-compulsive-disorder-100608210","NCT07198594","Accelerated rTMS Therapeutic Approach for Refractory Obsessive-Compulsive Disorder","A Study on the Efficacy and Safety of Accelerated Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder and Its Underlying Neurological Mechanisms","OCDTMS-IFC","Inclusion Criteria:\n\n* Volunteer subjects with Obsessive Compulsive Disorders (OCD) according to the Diagnostic and Statistical Manual of Mental Disorders (DSM V) criteria\n* without associated tics (\"Gilles de la Tourette\" Syndrome)\n* Age 18-60 years, right-handed\n* Disease severity: Yale-Brown Obsessive Compulsive Scale score ≥16 for OCD patients\n* Medication stable for at least 4 weeks\n* Resistant patients to standard treatments: partial but insufficient response (reduction of Y-BOCS score \\\u003C 35%) or lack of response to previous well conducted treatment including: optimal tolerated dose and adequate duration (\\> 12 weeks) of at least 2 Serotonin Reuptake Inhibitors (selective serotonin reuptake inhibitors, clomipramine), or 1 Serotonin Reuptake Inhibitors + 1 augmentation strategy (adjunction of an antipsychotic - such as risperidone or olanzapine or aripiprazole - or lithium or buspirone)\n* No systematic rTMS therapy in the past six months;\n* Signature of informed consent form;\n* Normal vision or corrected vision;\n* Capacity to complete protocol-specified tests.\n\nExclusion Criteria:\n\n* Abnormal cognitive status (assessed using MoCA with score \\\u003C24);\n* Other primary diagnosis than OCD (comorbid mild depression is tolerated)\n* Comorbid diagnosis of schizophrenia\u002F psychotic disorder, bipolar disorder, substance abuse or dependance3)\n* Significant self-harm intent or severe suicidal tendencies within the past year;\n* Irreversible visual or auditory impairment preventing completion of scales or related assessments;\n* Presence of metallic implants, such as pacemakers or stents;\n* Any current or potential medical, psychological, social, or geographical factors compromising patient safety or study participation;\n* Poor compliance;\n* Claustrophobia;\n* History of epilepsy or familial epilepsy\n* Pregnant or lactating women (women of childbearing potential must obtain a negative pregnancy test result prior to study commencement and employ medically approved contraceptive measures);\n* Deterioration or failure of vital organ function (cardiac, pulmonary, hepatic, renal, etc.); or unstable vital signs;\n* Conditions unsuitable for this stimulation site, such as increased intracranial pressure, elevated intraocular pressure, or glaucoma\n* History of or concomitant neurological disorders: cerebrovascular disease, central nervous system infections, Creutzfeldt-Jakob disease, Huntington's disease and Parkinson's disease, Lewy body dementia, traumatic brain injury dementia, other physical\u002Fchemical factors (drugs, alcohol, CO, etc.), significant somatic diseases (hepatic encephalopathy, pulmonary encephalopathy, etc.), intracranial space-occupying lesions (subdural haematoma, brain tumours), endocrine system disorders (thyroid disease, parathyroid disease), and dementia caused by vitamin deficiency or any other cause","60 Years",{"count":51,"type":21},20,[24],"The goal of this clinical trial is to learn if individualized accelerated repetitive transcranial magnetic stimulation (rTMS) targeting the inferior frontal cortex combined with symptom provocation works to treat obsessive-compulsive disorders (OCD) in adults. It will also learn about the safety of rTMS over right IFC. The main questions it aims to answer are:\n\n* Does rTMS using a new individualized IFC target relieve participants' OCD symptoms?\n* What medical problems do participants have when taking rTMS?\n\nParticipants will:\n\n* Take rTMS six times per day for 5 consecutive days\n* Visit the clinic once at baseline, the day and four weeks after treatment for checkups and tests",[55,56],"Obsessive Compulsive Disorder (OCD)","Obsessive - Compulsive Disorder","RECRUITING","2025-09-21",{"date":60,"type":32},"2025-09-30",{"date":62,"type":32},"2025-07-03",{"date":64,"type":21},"2027-12-31",{"name":38,"class":39},{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":40},"100551528","amygdala-mri-tis-for-depression-100551528","NCT06461260","Amygdala MRI-TIS for Depression","Safety, Efficacy and Neuroimaging Mechanisms of Amygdala Temporal Interference Stimulation Therapy for Depression","Inclusion Criteria:\n\n* Participants must be aged between 18 and 65, with no gender restrictions;\n* A diagnosis of depression made by the study physician based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5);\n* HAMD-17 score of 17 or higher;\n* Participants must not have changed their antidepressant medication regimen from 30 days prior to signing the informed consent form through the duration of the experiment;\n* Eligible individuals or their authorized representatives must demonstrate, as assessed by the study physician, a comprehensive understanding of the study's objectives and procedures, be capable of adhering to the requirements set forth in the study protocol, and provide their signature on the informed consent form.\n\nExclusion Criteria:\n\n* Eligible participants must not have a history of psychiatric or neurological disorders, as judged by the investigator, which may impact the evaluation of the study's efficacy;\n* Participants must not have a history of seizures or prior episodes of epilepsy;\n* The presence of metallic foreign objects within the cranial structure or metallic cardiac implants;\n* Participants must not have a diagnosis of organic brain disease, nor a history of significant cranial trauma or neurosurgical intervention;\n* Participants received electroconvulsive therapy or other physical therapies (such as transcranial magnetic stimulation therapy);\n* The researcher evaluated the individual's mental state and determined it to present a significant risk of suicidal ideation or behavior;\n* Pregnant or breastfeeding;\n* Participants who are concurrently engaged in other clinical interventional trials;\n* Participants presenting with other circumstances that the investigator deems unsuitable for the intervention being studied",{"count":74,"type":21},30,[24],"The study utilizes a non-invasive deep brain stimulation (temporal interference, TI) technique primarily targeting the amygdala to preliminarily explore the clinical efficacy and potential mechanisms of MRI-compatible TI technology in regulating the amygdala in depressive disorders, providing a more comprehensive basis for the application of TI technology.",[78],"Major Depressive Disorder",[78,80,81],"Deep Brain Stimulation","TI stimulation","2024-06-11",{"date":84,"type":32},"2024-06-14",{"date":86,"type":32},"2024-05-27",{"date":88,"type":21},"2025-04-28",{"name":38,"class":39},{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":97,"maxAge":17,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":103,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":110,"leadSponsor":111,"locationsCount":40},"100550882","amygdala-and-dlpfc-mri-tis-for-depression-in-adolescents-100550882","NCT06452849","Amygdala and dLPFC MRI-TIS for Depression in Adolescents","Temporal Interference Stimulation of Amygdala and dLPFC: A Randomized Controlled Trial for Adolescent Depression","Inclusion Criteria:\n\n* Participants must be aged between 14 and 18, with no gender restrictions;\n* A diagnosis of depression made by the study physician based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5);\n* HAMD-17 score of 17 or higher;\n* Participants must not have changed their antidepressant medication regimen from 30 days prior to signing the informed consent form through the duration of the experiment;\n* Eligible individuals or their authorized representatives must demonstrate, as assessed by the study physician, a comprehensive understanding of the study's objectives and procedures, be capable of adhering to the requirements set forth in the study protocol, and provide their signature on the informed consent form.\n\nExclusion Criteria:\n\n* Eligible participants must not have a history of psychiatric or neurological disorders, as judged by the investigator, which may impact the evaluation of the study's efficacy;\n* Participants must not have a history of seizures or prior episodes of epilepsy;\n* The presence of metallic foreign objects within the cranial structure or metallic cardiac implants;\n* Participants must not have a diagnosis of organic brain disease, nor a history of significant cranial trauma or neurosurgical intervention;\n* Participants received electroconvulsive therapy or other physical therapies (such as transcranial magnetic stimulation therapy); The researcher evaluated the individual's mental state and determined it to present a significant risk of suicidal ideation or behavior;\n* Pregnant or breastfeeding;\n* Participants who are concurrently engaged in other clinical interventional trials;\n* Participants presenting with other circumstances that the investigator deems unsuitable for the intervention being studied","14 Years",{"count":99,"type":21},60,[24],"The study utilizes a non-invasive deep brain stimulation (temporal interference, TI) technique primarily targeting the amygdala to preliminarily explore the clinical efficacy and potential mechanisms of MRI-compatible TI technology in regulating the amygdala in adolescent depressive disorders.",[78],[104,80,78,105,106],"Adolescents","Temporal Interference","Amygdala","2024-06-05",{"date":82,"type":32},{"date":86,"type":32},{"date":88,"type":21},{"name":38,"class":39},""]